<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03725696</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 16-721</org_study_id>
    <nct_id>NCT03725696</nct_id>
  </id_info>
  <brief_title>The Effect of Bariatric Surgery on Spermatogenesis</brief_title>
  <official_title>The Effect of Bariatric Surgery on Spermatogenesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Little is known about the effects of weight loss surgery on male reproductive health. This
      study will investigate the effect of bariatric surgery on male infertility by evaluating
      sexual health, blood hormone levels, and semen parameters before and after roux-en-y
      bariatric surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity is a worldwide epidemic that has numerous health consequences including male
      infertility. Prior studies have shown a variety of health benefits with bariatric surgery,
      including an improvement/resolution in diabetes and a significant improvement in serum
      testosterone levels. Based upon preliminary data from the literature, the investigators
      hypothesize that bariatric surgery is associated with a transient decrease followed by a
      robust long-term improvement in semen parameters including DNA fragmentation and oxidative
      stress. To test this hypothesis, the investigators propose a prospective observational study
      examining changes in hormone and semen parameters over the 12 months following Roux-en-Y
      gastric bypass surgery. The investigators will correlate these changes to weight loss,
      changes in subjective sexual function, and advanced semen parameters including DNA
      fragmentation. If successful, this study will conclusively identify a new modifiable cause
      for male infertility and suggest an additional medical indication for bariatric surgery in
      obese infertile men.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in sperm concentration</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Changes in sperm concentration on semen analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight loss</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Change in weight following bariatric surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sexual health</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Change in International Index of Erectile Function (IIEF) score, a validated questionnaire with scores ranging from 1 (significant erectile dysfunction to 30 (no erectile dysfunction).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in reproductive hormones</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Changes in FSH, LH, testosterone, and estrogen blood levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in seminal oxidative stress</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Changes in seminal reactive oxygen species</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sperm morphology</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Changes in percent normal sperm morphology on semen analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in seminal DNA fragmentation</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>Changes in seminal DNA fragmentation rate on semen analysis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Bariatric Surgery Candidate</condition>
  <condition>Sexual Function and Fertility Disorders</condition>
  <arm_group>
    <arm_group_label>Observational group</arm_group_label>
    <description>Patients who are booked for RYGB gastric bypass surgery and enroll in the study will undergo semen analysis, sexual health questionnaire (IIEF survey), and a blood hormonal panel before and after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Semen Analysis</intervention_name>
    <description>Sperm counts will be determined by semen analysis.</description>
    <arm_group_label>Observational group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Hormonal panel</intervention_name>
    <description>Blood test for LH, FSH, testosterone, and estradiol</description>
    <arm_group_label>Observational group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RYGB Gastric Bypass</intervention_name>
    <description>Roux-en-Y Gastric Bypass</description>
    <arm_group_label>Observational group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>IIEF Survey</intervention_name>
    <description>International Index of Erectile Function is a validated 5-question survey examining sexual health in men</description>
    <arm_group_label>Observational group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men between the ages of 18 and 50 scheduled for bariatric surgery who meet the above
        enrollment criteria will be offered enrollment in the study at the time of their
        preoperative clinic visit.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men aged 18-55

          -  Undergoing Roux-en-Y bariatric surgery

        Exclusion Criteria:

          -  History of undescended testes

          -  Prior scrotal surgery

          -  Known karyotypic abnormalities
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Lundy, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott Lundy</last_name>
    <phone>2163796134</phone>
    <email>lundys@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chytaine Hall</last_name>
    <phone>216-219-1131</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 24, 2018</study_first_submitted>
  <study_first_submitted_qc>October 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2018</study_first_posted>
  <last_update_submitted>November 1, 2018</last_update_submitted>
  <last_update_submitted_qc>November 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Scott Lundy</investigator_full_name>
    <investigator_title>Resident Physician</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

